3[9]Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in b1 prospective studies. Lancet,2002, 360:1903-1913.
4[10]Vasarn RS, Larson MG, Leip EP, et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohot study. Lancet, 2001, 358:1682-1686.
5[11]Guideline Subcommittee. 1999 World Health Organization-International Society of Hypertension Guideline for the Management of Hypertension. J Hypertens, 1999, 17:151-183.
6[12]European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 2003, 21:1011-1053.
7[13]The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med, 1997, 157:2413-2446.
8[14]Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002, 359:1004-1010.
